This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Jul 28;358(9278):256-7.

doi: 10.1016/S0140-6736(01)05493-9.

A role for phosphodiesterase type-4 inhibitors in COPD?

Affiliations

PMID: 11498207
DOI: 10.1016/S0140-6736(01)05493-9

Comment

A role for phosphodiesterase type-4 inhibitors in COPD?

D C Johnson. Lancet. 2001.

. 2001 Jul 28;358(9278):256-7.

doi: 10.1016/S0140-6736(01)05493-9.

Author

Affiliation

¹ Pulmonary and Critical Care Unit, Massachusetts General Hospital, Boston, MA 02114, USA. djohnson5@partners.org

PMID: 11498207
DOI: 10.1016/S0140-6736(01)05493-9

No abstract available

PubMed Disclaimer

Comment on

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study.
Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A, Ayres JG, Creemers JP, Schultze-Werninghaus G, Brambilla C, Barnes NC; International Study Group. Compton CH, et al. Lancet. 2001 Jul 28;358(9278):265-70. doi: 10.1016/S0140-6736(01)05481-2. Lancet. 2001. PMID: 11498212 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information